论文部分内容阅读
目的:总结氟铁龙(Furtulon简称FTL)治疗乳腺癌和胃肠道癌的疗效及临床经验,探讨其临床应用前景。方法:采用回顾性研究的方法,将应用FTL2个疗程以上的112例上述病种,分成术后辅助化疗组与晚期癌症(包括术后复发、转移)治疗组,并按不同肿瘤分类统计分析。用药方法采用FTL400mgTid×14d,休息14d为一疗程。连续6个疗程后休息3个月,再连续6疗程。乳腺癌加用三苯氧胺(TAM)10mgBid或甲孕酮(MAP)100mgtid或500mgqd;晚期胃肠道癌加用丝裂霉素(MMC)6mg/m2～8mg/m2,iv,dl。结果:随访1a～3a,术后辅助治疗组76例中,复发3例,复发率为3.9%;远处转移7例,转移率为9.2%,其余均健在。晚期癌症治疗组36例中,乳腺癌有效率为62.5%;胃癌、结肠癌和直肠癌的有效率分别为42.8%、37.5%和38.5%,总有效率为44.4%。本组用药4个疗程以上病例与用药4个疗程以下病例,无论是术后的辅助化疗还晚期的姑息治疗,其疗效均相似(P<0.05)。全组除1例发生严重腹泻对症处理外,其余均无明显毒副作用。结论:氟铁龙对胃肠道恶性肿瘤,尤其是乳腺癌有较好的疗效,可以作为乳腺癌,胃肠道癌的术后辅助化疗,也可应用晚期乳腺癌、胃肠道癌的治疗及术后复发转移的再治疗。
Objective: To summarize the curative effect and clinical experience of treatment of breast cancer and gastrointestinal cancer by Furtulon (FTL), and to explore its clinical application prospect. Methods: A retrospective study was conducted to divide the 112 patients with above two courses of FTL into two groups: the adjuvant chemotherapy group and the advanced cancer group (including postoperative recurrence and metastasis), and classified according to different tumor types. Medication using FTL400mgTid × 14d, rest 14d for a course of treatment. 6 consecutive months of rest after 3 months, and then for 6 courses. Breast cancer plus tamoxifen (TAM) 10mgBid or medroxyprogesterone (MAP) 100mgtid or 500mgqd; advanced gastrointestinal cancer with mitomycin (MMC) 6mg / m2 ~ 8mg / m2, iv, dl. Results: In the follow-up of 1a ~ 3a, among the 76 patients in the postoperative adjuvant therapy group, 3 cases were relapsed, the recurrence rate was 3.9%, distant metastasis in 7 cases and metastasis rate was 9.2%. In 36 cases of advanced cancer treatment group, the effective rate of breast cancer was 62.5%. The effective rates of gastric cancer, colon cancer and rectal cancer were 42.8%, 37.5% and 38.5% respectively, and the total effective rate was 44.4%. This group of medication for more than 4 courses of treatment and medication for the following 4 courses, both postoperative adjuvant chemotherapy and late palliative treatment, the efficacy was similar (P <0.05). The whole group except one case of severe diarrhea symptomatic treatment, the rest were no obvious side effects. Conclusion: The treatment of gastrointestinal cancer, especially breast cancer, has a good effect and can be used as postoperative adjuvant chemotherapy for breast cancer and gastrointestinal cancer. It can also be used in the treatment of advanced breast cancer and gastrointestinal cancer And postoperative recurrence and metastasis of re-treatment.